Молодежный инновационный вестникМолодежный инновационный вестник2415-7805Федеральное государственное бюджетное образовательное учреждение высшего образования "Воронежский государственный медицинский университет имени Н.Н. Бурденко" Министерства здравоохранения Российской Федерации8359UnclassifiedANALYSIS OF THE NT-PROBNP LEVEL IN PATIENTS WITH CHF AND COVID-19GlavatskikhYuliya OlegovnaYuliyag36@gmail.comhttps://orcid.org/0000-0002-2398-5987TokmachevRoman Evgenyevichr-tokmachev@mail.ruhttps://orcid.org/0000-0001-6379-4635BudnevskayaSofia Andreevnayuliyag36@gmail.comhttps://orcid.org/0000-0003-3649-5642DrobyshevaValeria Romanovnadrobyshevavr@gmail.comhttps://orcid.org/0000-0001-6636-6644Voronezh State Medical University named after V.I. N.N. Burdenko2004202312S21031051402202326032023Copyright © 2023, Glavatskikh Y.O., Tokmachev R.E., Budnevskaya S.A., Drobysheva V.R.2023<p><strong>Background. </strong>Since the beginning of the pandemic, the number of coronavirus infections has reached 662,221,274 and the number of deaths has reached 6,701,780. These figures are largely due to the decompensation of heart failure as a result of the addition of SARS-CoV 2 infection. Increased levels of cardiac biomarkers during coronavirus infection reflect excess inflammation, viral load, cytokine storm, and an atherothrombotic process that can cause direct or indirect heart damage.</p> <p><strong>Objective.</strong> To study the level of NT-proBNP in patients with chronic heart failure who have had COVID-19.</p> <p><strong>Materials and methods.</strong>The study included patients aged 40 to 70 years diagnosed with CHF of ischemic genesis hospitalized with a positive polymerase chain reaction (PCR) smear for SARS-C infection about V-2 (n = 60). The control group consisted of patients hospitalized with a positive PCR smear for SARS-C infection about V-2, without signs of HF in the anamnesis ( n=20). All patients underwent laboratory methods: general clinical and enzyme immunoassays of blood with determination of NT-proBNP levels.</p> <p><strong>Results. </strong>The average NT-proBNP level in patients with CHF and Covid-19 was significantly higher than its value in patients without a history of CVD. In patients with source III FC CHF (subgr. 1. 3) the level of the biomarker significantly exceeded its value in patients witho II FC CHF and in patients with I FC CHF (subg.1.1).. The ratio of the odds of a favorable course of CHF and Covid-19 or the transfer to the ICU of patients with CHF and Covid-19 depending on the level of Nt-proBNP (threshold value of ˃300 pg / ml) was studied. The resulting OR was 12.27, [95% CI 1.53567; 98.1617]. Consequently, the probability of not getting into the ICU in patients with an NT-proBNP level below the threshold is 12.27 times lower than in patients with an Nt-proBNP level of ˃300 pg / ml. Also, the ratio of the chances of a favorable course of CHF and Covid-19 or death depending on the level of Nt-proBNP was studied. (threshold value ˃300 pg/ml). The resulting OR was 2.43 [95% CI 0.564593; 10.5233]. Therefore, the probability of non-occurrence of such a checkpoint as death in patients with an NT-proBNP level below the threshold is 2.43 times lower than in patients with an Nt-proBNP level of ˃300 pg / ml.</p> <p><strong>Conclusion.</strong>Threshold values for cardiac biomarkera (NT-proBNP) for stratification and isolation of risk groups among patients with Covid-19, CHF and Covid-19 have been determined. In patients with Covid-19 and CHF, a strong association has been found between high levels of the cardiac biomarker (Nt-proBNP) and a negative short-term prognosis (ICU transfer/death). Thus, in patients with CHF and Covid-19 against the background of hypoxia, systemic subclinical inflammation, damage and apoptosis of cardiomyocytes occur, which as a result leads to structural-functional and electrical remodeling of the ventricles with decompensation of heart failure.</p>chronic heart failurecovid-19Cardiac biomarkersNT-proBNPхроническая сердечная недостаточностьcovid-19Сердечные биомаркерыNT-proBNP1.Budnevsky AV, Shurupova AD, Kravchenko AY, Tokmachev RE. Clinical efficacy of acute respiratory viral infections prevention in patients with chronic heart failure. Terapevticheskii arkhiv. 2019;91(3):36–41.2.Banin I, Budnevsky A, Grechkin V. et al. The experience of surfactant therapy in severe COVID-19 pneumonia: A case report. International Journal of Biomedicine. 2021;11(2):177–80.3.Tokmachev R, Kravchenko A, Budnevsky A et al. Features of the functional status and cytokine profile of patients with chronic heart failure in combination with chronic obstructive pulmonary disease. International Journal of Biomedicine. 2021;11(1):9–13.4.Коморбидность хронической сердечной недостаточности и хронической обструктивной болезни легких / Ю. О. Главатских, Р. Е. Токмачев, Е. С. Дробышева [и др.] // Forcipe. – 2021. – Т. 4, № S1. – С. 825. – EDN HDENUS.5.Диагностические, прогностические и терапевтические возможности использования теста 6-минутной ходьбы у пациентов с хронической сердечной недостаточностью / Будневский А.В., Кравченко А.Я., Токмачев Р.Е. [и др.]// Кардиоваскулярная терапия и профилактика. 2020;19(6):2460. https://doi.org/10.15829/1728-8800-2020-2460